ArticlePaediatric drugs2026
Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis.
Article in Paediatric drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceSirolimus is increasingly used for complex vascular and lymphatic anomalies in neonates and infants. While dyslipidemia is a known adverse effect in adults, the incidence, timing, and severity in this population remain poorly characterized.
objectiveThe aim of this study was to evaluate the reporting odds and characteristics of sirolimus-associated dyslipidemia in neonates and infants compared with older populations. DESIGN, SETTING, AND
participantsThis study combined a single-center retrospective cohort study and global pharmacovigilance analysis. The clinical cohort included neonates and infants treated with sirolimus at Nagoya University Hospital (October 2018-September 2025). The pharmacovigilance analysis utilized VigiBase (up to September 1, 2025) to perform age-stratified disproportionality analyses. MAIN OUTCOMES AND MEASURES: In the clinical cohort, lipid profiles (total cholesterol, LDL-C, triglycerides) were assessed pre- and post-treatment. In VigiBase, adjusted reporting odds ratios (aRORs) for dyslipidemia and time-to-onset (TTO) were estimated across age groups, adjusting for sex, region, and concomitant medications.
resultsThe cohort included 10 patients (median age, 44.5 days). Post-initiation, 100% developed hypertriglyceridemia and 90% developed hypercholesterolemia. In VigiBase (17,802 sirolimus-related reports), the dyslipidemia reporting signal was highest in infants (28 days-23 months), with an aROR of 147.08 (95% CI 79.67-271.54), substantially exceeding that in adults aged 18-45 years (aROR 2.31; 95% CI 1.75-3.06). Among infant reports with available TTO data, median TTO was 11.0 days (IQR 5.5-15.8), compared with 29.5 days in adults. CONCLUSIONS AND RELEVANCE: Neonates and infants showed a markedly stronger dyslipidemia reporting signal than older age groups, and lipid abnormalities were common in the clinical cohort. These findings support baseline lipid assessment and early monitoring after sirolimus initiation in very young patients, including within the first two weeks of therapy. The pharmacovigilance findings should be interpreted as hypothesis generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.